ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2018
Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
Open access · bronzeAbstract readMulticenter Study
In one paragraph
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Antibodies as biomarkers for cancer risk: a systematic review.Clinical and experimental immunology · 2022Pooled it
- Variables Affecting CA15.3 Tumor Antigen Expression and Antibodies against It in Female National Health and Nutritional Survey Participants.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Incessant ovulation: a review of its importance in predicting cancer risk.Frontiers in oncology · 2023Article
- Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case-Control Study in Northern Sweden.Translational oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 20 institutions in 13 countries.
Daniel W CramerEpidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts. dcramer@bwh.harvard.edu r.kaaks@dkfz.de.
Raina N FichorovaHarvard Medical School, Boston, Massachusetts.
Kathryn L TerryEpidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
Hidemi YamamotoLaboratory of Genital Tract Biology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
Allison F VitonisEpidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
Eva ArdanazNavarra Public Health Institute, Pamplona, Spain.
Dagfinn AuneSchool of Public Health, Imperial College London, London, United Kingdom.
Heiner BoeingGerman Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Jenny BrändstedtDepartment of Clinical Sciences, Lund University, Sweden.
Marie-Christine Boutron-RuaultCESP, INSERM U1018, Univ. Paris-Sud, UVSQ, Université Paris-Saclay, Villejuif, France.ORCID 0000-0002-5956-5693
Maria-Dolores ChirlaqueDepartment of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
Miren DorronsoroPublic Health Direction and Biodonostia Research Institute and Ciberesp, Basque Regional Health Department, San Sebastian, Spain.
Laure DossusInternational Agency for Research on Cancer, Lyon, France.
Eric J DuellUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology (ICO), Barcelona, Spain.
Inger T GramFaculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Marc GunterInternational Agency for Research on Cancer, Lyon, France.
Louise HansenDiet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark.
Annika IdahlDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Theron JohnsonDivision of Cancer Epidemiology, German Cancer Research Center, (DKFZ) Heidelberg, Germany.
Kay-Tee KhawSchool of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Vittorio KroghEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Marina KvaskoffCESP, INSERM U1018, Univ. Paris-Sud, UVSQ, Université Paris-Saclay, Villejuif, France.
Amalia MattielloDiparmento di Medicina Clinica e Chirugria Federico II University, Naples, Italy.
Giuseppe MatulloDepartment of Medical Sciences, University of Torino, Italian Institute for Genomic Medicine -IIGM (FKA HuGeF), Torino, Italy.
Melissa A MerrittSchool of Public Health, Imperial College London, London, United Kingdom.
Björn NodinDepartment of Clinical Sciences Lund, Oncology and Pathology, Lund University, Lund, Sweden.
Philippos OrfanosHellenic Health Foundation, Athens, Greece.
N Charlotte Onland-MoretJulis Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Domenico PalliCancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy.
Eleni PeppaHellenic Health Foundation, Athens, Greece.
J Ramón QuirósPublic Health Directorate, Asturias, Spain.
Maria-Jose Sánchez-PerezEscuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.Granada, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
Gianluca SeveriCESP, INSERM U1018, Univ. Paris-Sud, UVSQ, Université Paris-Saclay, Villejuif, France.
Anne TjønnelandDiet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Rosario TuminoCancer Registry and Histopathology Department, "Civic - M.P. Arezzo" Hospital, ASP Ragusa, Italy.
Elisabete WeiderpassDepartment of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center, (DKFZ) Heidelberg, Germany.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center, (DKFZ) Heidelberg, Germany. dcramer@bwh.harvard.edu r.kaaks@dkfz.de.
Brigham and Women's Hospital · USGerman Cancer Research Center · DEUniversité Paris-Sud · FRCentre international de recherche sur le cancer · FRDanish Cancer Society · DKImperial College London · GBLund University · SENational and Kapodistrian University of Athens · GRAzienda Usl 8 Arezzo · ITBiogipuzkoa Health Research Institute · ESFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Institute of Human Nutrition · DEGobierno del Principado de Asturias · ESHellenic Health Foundation · GRInstitut d'Investigació Biomédica de Bellvitge · ESInstituto de Investigación Biosanitaria de Granada · ESInstituto de Salud Pública de Navarra · ESInstituto Murciano de Investigación Biosanitaria · ESItalian institute for Genomic Medicine · IT
Funding
Mucins and immune cell interactions in ovarian cancer pathogenesis & progressionR35CA197605 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2016 to 2022
$6.9MScreening and Risk Biomarkers for Ovarian Cancer in EPIC SpecimensR01CA158119 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2012 to 2015
$2.0MCancer Research UK 14136Cancer Research UK 16491Cancer Research UK C570/A16491Cancer Research UK UK C8221/A19170Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1NCI NIH HHS R01 CA158119NCI NIH HHS R35 CA197605World Health Organization 001
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedBiomarkers, TumorCA-125 AntigenCase-Control StudiesCohort StudiesFemaleHumansMiddle AgedOvarian NeoplasmsProspective StudiesRisk FactorsBiomarkers, TumorCA-125 Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.